|
9
|
|
Neoadjuvant nivolumab with or without visugromab in muscle-invasive bladder cancer: the phase 2a GDFATHER-NEO trial.
(nature.com)
|
Necchi A
…
Lichtenegger FS
Nature Medicine
2026-10-24
|
#immunotherapy
#bladder cancer
#neoadjuvant
#clinical trial
#checkpoint inhibitor
|
|
9
|
|
Tarlatamab-Durvalumab Maintenance for Extensive-Stage Small-Cell Lung Cancer.
(nejm.org)
|
Perol M
…
Sands J
New England Journal of Medicine
2026-10-24
|
#cancer
#clinical trial
#immunotherapy
#lung cancer
#bispecific-antibodies
|
|
9
|
|
Anbenitamab plus HB1801 for HER2-Positive Advanced Breast Cancer.
(nejm.org)
|
Wang J
…
Xu B
New England Journal of Medicine
2026-10-24
|
#breast cancer
#clinical trial
#her2
#immunotherapy
#chemotherapy
|
|
9
|
|
Durvalumab, Tremelimumab, and Enfortumab Vedotin in Muscle-Invasive Bladder Cancer.
(nejm.org)
|
Powles T
…
Drakaki A
New England Journal of Medicine
2026-10-24
|
#cancer
#clinical trial
#immunotherapy
#bladder
#neoadjuvant
|
|
9
|
|
Relatlimab plus nivolumab versus nivolumab for advanced melanoma: 5-year survival and biomarker analyses of the phase 3 RELATIVITY-047 trial.
(nature.com)
|
Long GV
…
Tawbi H
Nature Medicine
2026-10-24
|
#melanoma
#immunotherapy
#checkpoint-inhibitors
#biomarker
#survival
|